Brief: Precigen Announces Positive Early Stage Data In Patients With Recurrent Respiratory Papillomatosis

Precigen

24/01/2023 23:21

Jan 24 (Reuters) - Precigen Inc  PGEN.O :
    * PRECIGEN ANNOUNCES POSITIVE PHASE 1 DOSE ESCALATION AND
EXPANSION COHORT DATA FOR INVESTIGATIONAL OFF-THE-SHELF
PRGN-2012 ADENOVERSE™ IMMUNOTHERAPY IN PATIENTS WITH RECURRENT
RESPIRATORY PAPILLOMATOSIS
    * PRECIGEN INC - COMPANY TO OUTLINE REGULATORY STRATEGY IN
RRP AS
US FOOD AND DRUG ADMINISTRATION (FDA) DISCUSSIONS ADVANCE
    * PRECIGEN INC - PHASE 2 STUDY IS ENROLLING PATIENTS WITH A
TOTAL
OF 32 PATIENTS ENROLLED AT DOSE LEVEL 2 TO DATE
    * PRECIGEN INC - PRGN-2012 TREATMENT AT DOSE LEVEL 2
SIGNIFICANTLY
REDUCED NEED FOR SURGERIES IN SEVERE, AGGRESSIVE RRP PATIENTS
    * PRECIGEN INC - REPEATED ADMINISTRATIONS OF PRGN-2012 WERE
WELL-TOLERATED

Source text for Eikon:  ID:nPn5DJ93ha 
Further company coverage:  PGEN.O 
 ((Reuters.Briefs@thomsonreuters.com;))